Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

revvity inc. - RVTY

RVTY

Close Chg Chg %
85.69 0.92 1.07%

Pre-Market

86.61

+0.92 (1.07%)

Volume: 1.19M

Last Updated:

Sep 5, 2025, 4:00 PM EDT

Trade Now

Company Overview: revvity inc. - RVTY

RVTY Key Data

Open

$85.71

 Day Range

85.51 - 88.12

52 Week Range

81.36 - 133.96

 Market Cap

$9.95B

Shares Outstanding

116.07M

 Public Float

115.59M

Beta

0.95

 Rev. Per Employee

N/A

P/E Ratio

36.36

 EPS

$2.36

Yield

32.67%

 Dividend

$0.07

EX-DIVIDEND DATE

Oct 17, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.18M

  

RVTY Performance

1 Week
 
 -3.85%
 
1 Month
 
 -0.23%
 
3 Months
 
 -5.80%
 
1 Year
 
 -24.93%
 
5 Years
 
 -24.20%
 

RVTY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About revvity inc. - RVTY

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

RVTY At a Glance

Revvity, Inc.
77 Citypoint 4th Avenue
Waltham, Massachusetts 02451
Phone 1-781-663-6900 Revenue 2.76B
Industry Medical Specialties Net Income 295.83M
Sector Health Technology 2024 Sales Growth 0.162%
Fiscal Year-end 12 / 2025 Employees 11,000
View SEC Filings

RVTY Valuation

P/E Current 36.363
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 46.338
Price to Sales Ratio 4.976
Price to Book Ratio 1.756
Price to Cash Flow Ratio 21.818
Enterprise Value to EBITDA 18.929
Enterprise Value to Sales 5.76
Total Debt to Enterprise Value 0.21

RVTY Efficiency

Revenue/Employee 250,456.909
Income Per Employee 26,893.909
Receivables Turnover 4.356
Total Asset Turnover 0.212

RVTY Liquidity

Current Ratio 3.598
Quick Ratio 3.035
Cash Ratio 1.783

RVTY Profitability

Gross Margin 48.009
Operating Margin 14.901
Pretax Margin 11.475
Net Margin 10.738
Return on Assets 2.181
Return on Equity 3.643
Return on Total Capital 2.575
Return on Invested Capital 2.556

RVTY Capital Structure

Total Debt to Total Equity 43.379
Total Debt to Total Capital 30.255
Total Debt to Total Assets 26.837
Long-Term Debt to Equity 43.068
Long-Term Debt to Total Capital 30.038
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Revvity Inc. - RVTY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
5.07B 3.31B 2.75B 2.76B
Sales Growth
+33.95% -34.64% -16.95% +0.16%
Cost of Goods Sold (COGS) incl D&A
2.39B 1.55B 1.43B 1.43B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
358.00M 427.00M 431.77M 427.85M
Depreciation
67.30M 56.40M 66.70M 68.47M
Amortization of Intangibles
290.70M 370.60M 365.07M 359.38M
COGS Growth
+33.19% -35.02% -7.91% +0.28%
Gross Income
2.68B 1.76B 1.32B 1.32B
Gross Income Growth
+34.64% -34.30% -24.91% +0.04%
Gross Profit Margin
+52.89% +53.16% +48.07% +48.01%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.23B 979.61M 922.70M 912.14M
Research & Development
274.97M 221.62M 216.58M 196.84M
Other SG&A
957.94M 757.99M 706.12M 715.30M
SGA Growth
+27.01% -20.54% -5.81% -1.14%
Other Operating Expense
- - - -
-
Unusual Expense
103.80M 54.18M 132.85M 55.82M
EBIT after Unusual Expense
1.34B 726.94M 266.64M 354.70M
Non Operating Income/Expense
38.65M 28.85M 15.15M 57.70M
Non-Operating Interest Income
2.24M 3.59M 72.13M 73.19M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
102.13M 103.95M 98.81M 96.28M
Interest Expense Growth
+105.44% +1.79% -4.95% -2.57%
Gross Interest Expense
102.13M 103.95M 98.81M 96.28M
Interest Capitalized
- - - -
-
Pretax Income
1.28B 651.84M 182.98M 316.13M
Pretax Income Growth
+41.21% -49.07% -71.93% +72.77%
Pretax Margin
+25.26% +19.68% +6.65% +11.47%
Income Tax
336.60M 139.16M 3.47M 33.05M
Income Tax - Current - Domestic
213.00M 143.19M 48.98M 59.75M
Income Tax - Current - Foreign
172.94M 101.89M 78.15M 75.54M
Income Tax - Deferred - Domestic
(34.04M) (61.38M) (80.46M) (45.37M)
Income Tax - Deferred - Foreign
(15.30M) (44.54M) (43.20M) (56.86M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
943.28M 512.68M 179.50M 283.07M
Minority Interest Expense
- - - -
-
Net Income
943.28M 512.68M 179.50M 283.07M
Net Income Growth
+29.55% -45.65% -64.99% +57.70%
Net Margin Growth
+18.62% +15.48% +6.53% +10.27%
Extraordinaries & Discontinued Operations
- 56.50M (297.88M) 12.76M
Discontinued Operations
- 56.50M (297.88M) 12.76M
Net Income After Extraordinaries
943.28M 569.18M (118.38M) 295.83M
Preferred Dividends
- - - -
-
Net Income Available to Common
943.28M 569.18M (118.38M) 295.83M
EPS (Basic)
8.1202 4.5117 -0.9493 2.4099
EPS (Basic) Growth
+24.39% -44.44% -121.04% +353.86%
Basic Shares Outstanding
116.17M 126.16M 124.70M 122.76M
EPS (Diluted)
8.0848 4.5021 -0.9493 2.4086
EPS (Diluted) Growth
+24.48% -44.31% -121.09% +353.72%
Diluted Shares Outstanding
116.67M 126.43M 124.81M 122.82M
EBITDA
1.81B 1.21B 831.26M 838.37M
EBITDA Growth
+42.55% -33.07% -31.19% +0.86%
EBITDA Margin
+35.62% +36.48% +30.22% +30.43%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 116.438
Number of Ratings 19 Current Quarters Estimate 1.136
FY Report Date 09 / 2025 Current Year's Estimate 4.867
Last Quarter’s Earnings 1.18 Median PE on CY Estimate N/A
Year Ago Earnings 4.90 Next Fiscal Year Estimate 5.384
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 17 18 18
Mean Estimate 1.14 1.54 4.87 5.38
High Estimates 1.16 1.64 4.95 5.64
Low Estimate 1.12 1.51 4.84 5.20
Coefficient of Variance 0.89 1.97 0.53 2.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 4 4 4
HOLD 6 6 7
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Revvity Inc. - RVTY

Date Name Shares Transaction Value
Feb 20, 2025 Anita Gonzales Please See Remarks 3,790 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $112.26 per share 425,465.40
Feb 20, 2025 Anita Gonzales Please See Remarks 3,873 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $112.26 per share 434,782.98
Feb 20, 2025 Anita Gonzales Please See Remarks 3,942 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $112.26 per share 442,528.92
Feb 20, 2025 Maxwell Krakowiak Please See Remarks 12,776 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $112.26 per share 1,434,233.76
Feb 7, 2025 Prahlad Ramadhar Singh Please See Remarks; Director 57,838 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Maxwell Krakowiak Please See Remarks 15,784 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Miriame Victor Please See Remarks 11,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Miriame Victor Please See Remarks 14,288 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Miriame Victor Please See Remarks 10,128 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 1,252,732.32
Feb 7, 2025 Tajinder S. Vohra Please See Remarks 19,345 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 2,392,783.05
Feb 7, 2025 Prahlad Ramadhar Singh Please See Remarks; Director 106,258 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Prahlad Ramadhar Singh Please See Remarks; Director 85,338 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 10,555,457.22
Feb 7, 2025 Joel S. Goldberg Please See Remarks 13,656 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Joel S. Goldberg Please See Remarks 37,689 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Joel S. Goldberg Please See Remarks 32,750 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $123.69 per share 4,050,847.50
Feb 7, 2025 Tajinder S. Vohra Please See Remarks 9,069 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 7, 2025 Tajinder S. Vohra Please See Remarks 22,625 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 10, 2024 Tajinder S. Vohra Please See Remarks 21,806 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $122.99 per share 2,681,919.94

Revvity Inc. in the News